DRMA vs DWTX

Dermata Therapeutics, Inc. vs Dogwood Therapeutics, Inc. — Valuation Comparison 2026

DRMA

Biotechnology
Dermata Therapeutics, Inc.
Quality
2.8
out of 10
Value Trap
27
LOW
Price
$1.35
Last close
Models
7/13
Active
VS

DWTX

Biotechnology
Dogwood Therapeutics, Inc.
Quality
3.6
out of 10
Value Trap
37
LOW
Price
$1.67
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DRMA Fair ValueDRMA Upside DWTX Fair ValueDWTX Upside
Bayesian DCF Intrinsic $1.31 -3.2% $0.56 -61.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.09 -93.3% $0.05 -96.7%
Dynamic NAV Asset-Based $1.26 -6.3% $0.69 -52.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRMA vs DWTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRMA vs DWTX — Which Stock Is More Undervalued?

DWTX scores higher with a 3.6/10 quality rating vs DRMA's 2.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Dermata Therapeutics, Inc. (DRMA) and Dogwood Therapeutics, Inc. (DWTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRMA currently trades at $1.35 with a QOC of 2.8/10, while DWTX trades at $1.67 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).